Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,191.1	$ 1,133.1	$ 3,514.6	$ 3,536.5
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2]	613.3	596.2	1,777.2	1,794.7
CSCA | Cough/cold/allergy/sinus
Disaggregation of Revenue [Line Items]
Net sales	[2]	125.8	113.8	379.3	364.6
CSCA | Infant nutritionals
Disaggregation of Revenue [Line Items]
Net sales	[2]	93.3	112.4	274.8	325.0
CSCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[2]	85.7	96.8	262.7	282.7
CSCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[2]	83.0	95.4	289.5	290.6
CSCA | Smoking cessation
Disaggregation of Revenue [Line Items]
Net sales	[2]	77.1	72.8	220.9	209.9
CSCA | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales	[2]	54.2	0.0	54.2	0.0
CSCA | Natural health and vitamins, minerals and dietary supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	3.3	5.0	10.6	12.3
CSCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[2]	1.8	20.4	43.8	78.6
CSCA | Other CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	89.1	79.6	241.4	231.0
CSCI
Disaggregation of Revenue [Line Items]
Net sales		347.5	334.2	1,025.8	1,069.9
CSCI | Cough/cold/allergy/sinus
Disaggregation of Revenue [Line Items]
Net sales		93.4	94.8	263.2	278.2
CSCI | Oral self-care
Disaggregation of Revenue [Line Items]
Net sales		22.8	0.0	22.8	0.0
CSCI | Natural health and vitamins, minerals and dietary supplements
Disaggregation of Revenue [Line Items]
Net sales		31.0	32.2	86.4	93.3
CSCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales		72.3	70.5	235.0	246.3
CSCI | Personal care and derma-therapeutics
Disaggregation of Revenue [Line Items]
Net sales		56.0	60.0	191.2	215.3
CSCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales		26.8	30.2	79.5	88.7
CSCI | Other CSCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	45.2	46.5	147.7	148.1
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 230.3	$ 202.7	$ 711.6	$ 671.9

[1] Derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

[3] Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[4] Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.